Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.
Christopher A. Yasenchak(Willamette Valley Cancer Institute and Research Center), Jonathan W. Friedberg(University of Rochester), Jerome H. Goldschmidt, Trevor Newhook(Seagen (United States)), Rodolfo Bordoni(Georgia Cancer Specialists), Robert B. Sims(Seagen (United States)), Dipti Patel‐Donnelly(Orthopaedic Research of Virginia), Tim Larson(New York University), Andres Forero‐Torres(Kirklin Clinic), Ralph V. Boccia(Center for Cancer and Blood Disorders), Vivian Jean M. Cline(Texas Oncology)
Cited by 3
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425